EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

No dose adjustment of metformin or substrates of organic cation transporters ( OCT )1 and OCT2 and multidrug and toxin extrusion protein ( MATE )1/ 2K with fostemsavir coadministration based on modeling approaches

Dung Nguyen iD, Xiusheng Miao, Kunal Taskar, Mindy Magee, Pete Gorycki, Katy Moore, Guoying Tai

Pharmacology Research & Perspectives · 2024

DOI: 10.1002/prp2.1238 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2024. Verfasst von Dung Nguyen und 6 weiteren Autor:innen. Beteiligte Einrichtung: GlaxoSmithKline, Collegeville, Pennsylvania, USA. Hauptthemen laut MEDLINE: Metformin, Drug Interactions, Organic Cation Transport Proteins, Organic Cation Transporter 2. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Fostemsavir is an approved gp120‐directed attachment inhibitor and prodrug for the treatment of human immunodeficiency virus type 1 infection in combination with other antiretrovirals (ARVs) in heavily treatment‐experienced adults with multi‐drug resistance, intolerance, or safety concerns with their current ARV regimen. Initial in vitro studies indicated that temsavir, the active moiety of fostemsavir, and its metabolites, inhibited organic cation transporter (OCT)1, OCT2, and multidrug and toxin extrusion transporters (MATEs) at tested concentration of 100 uM, although risk assessment based on the current Food and Drug Administration in vitro drug–drug interaction (DDI) guidance using the mechanistic static model did not reveal any clinically relevant inhibition on OCTs and MATEs. However, a DDI risk was flagged with EMA static model predictions. Hence, a physiologically based pharmacokinetic (PBPK) model of fostemsavir/temsavir was developed to further assess the DDI risk potential of OCT and MATEs inhibition by temsavir and predict changes in metformin (a sensitive OCT and MATEs substrate) exposure. No clinically relevant impact on metformin concentrations across a wide range of temsavir concentrations was predicted; therefore, no dose adjustment is recommended for metformin when co‐administered with fostemsavir.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminDrug InteractionsOrganic Cation Transport ProteinsOrganic Cation Transporter 2OrganophosphatesHumansModels, BiologicalAnimalsOrganic Cation Transporter 1Anti-HIV AgentsOctamer Transcription Factor-1HIV InfectionsPiperazines

Stichwörter der Autor:innen

DDI with MetforminFostemsavirPBPK model

Substanzen

MetforminOrganic Cation Transport ProteinsOrganic Cation Transporter 2OrganophosphatesfostemsavirSLC47A1 protein, humanSLC22A2 protein, humanOrganic Cation Transporter 1SLC47A2 protein, humanAnti-HIV Agents

Autor:innen und Institutionen

  • GlaxoSmithKline, Collegeville, Pennsylvania, USA.
  • GlaxoSmithKline, Ware, UK.
  • Allucent, Cary, North Carolina, USA.

ORCID-Profile: Dung Nguyen

Zitieren

APA

Nguyen, D., Miao, X., Taskar, K., Magee, M., Gorycki, P., Moore, K., & Tai, G. (2024). No dose adjustment of metformin or substrates of organic cation transporters ( OCT )1 and OCT2 and multidrug and toxin extrusion protein ( MATE )1/ 2K with fostemsavir coadministration based on modeling approaches. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.1238

Vancouver

Nguyen D, Miao X, Taskar K, Magee M, Gorycki P, Moore K, et al. No dose adjustment of metformin or substrates of organic cation transporters ( OCT )1 and OCT2 and multidrug and toxin extrusion protein ( MATE )1/ 2K with fostemsavir coadministration based on modeling approaches. Pharmacology Research & Perspectives. 2024. doi:10.1002/prp2.1238

BibTeX
@article{Nguyen2024,
  author = {Nguyen, Dung and Miao, Xiusheng and Taskar, Kunal and Magee, Mindy and Gorycki, Pete and Moore, Katy and Tai, Guoying},
  title = {No dose adjustment of metformin or substrates of organic cation transporters ( OCT )1 and OCT2 and multidrug and toxin extrusion protein ( MATE )1/ 2K with fostemsavir coadministration based on modeling approaches},
  journal = {Pharmacology Research & Perspectives},
  year = {2024},
  doi = {10.1002/prp2.1238}
}
Kostenlos starten →